Last reviewed · How we verify
NCT07285694
An Open-label, Multicenter Phase 1/2 Study to Evaluate the Safety and Efficacy of AB-3028 in Patients With Castration Resistant Prostate Cancer (CRPC)
Phase 1/Phase 2 trial testing AB-3028 in Metastatic Castration Resistant Prostate Cancer (mCRPC) in 190 participants. Currently enrolling.
1 May 2029
Quick facts
| Lead sponsor | Arsenal Biosciences, Inc. |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 190 |
| Start date | 9 January 2026 |
| Primary completion | 1 May 2029 |
| Estimated completion | 1 May 2031 |
| Sites | 9 locations across United States |
Drugs / interventions tested
- AB-3028 — full drug profile →
Conditions studied
- Metastatic Castration Resistant Prostate Cancer (mCRPC) — all drugs for Metastatic Castration Resistant Prostate Cancer (mCRPC) →
Sponsor
Arsenal Biosciences, Inc. — full company profile →
Who can join
18 and older, male only, with Metastatic Castration Resistant Prostate Cancer (mCRPC). Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Safety and tolerability of AB-3028
Time frame: From AB-3028 infusion up to 24 months post-infusion
To assess safety and tolerability of increasing dose levels of AB-3028 in successive cohorts of subjects with metastatic CRPC to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of AB-3028
Sponsor's own description
This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07285694
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metastatic Castration Resistant Prostate Cancer (mCRPC)
Currently open trials in the same condition.
- NCT06894511 — An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in · Phase 2 · active not recruiting
- NCT03460977 — A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular · Phase 1 · recruiting
Other Arsenal Biosciences, Inc. trials
Trials by the same sponsor.
- NCT06245915 — AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC) · Phase 1, PHASE2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07285694 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Arsenal Biosciences, Inc.
- Last refreshed: 3 June 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07285694.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing